NK Sentiment and Impact on Affimed
Insights - Biotech (XBI) had a rocky 2022, seeing a near vertical drop in 1H 2022 and settling in around the low-$80 range in the second half … Continue Reading
PremiumAuthor Archives: D Mero
Looking Back on 2022 Name Updates
Research - Ending a rather difficult 2022 with a few quick notes on names that were written about this year. Jounce’s $67M Asset SaleGilead acquired the remaining … Continue Reading
Premium
Notes from KOL on AFM13+NK ASH2022 Data
Insights - Yesterday, Slingshot Insights had a call with a lymphoma KOL on Affimed’s (AFMD) AFM13+NK data that was presented at ASH earlier in December. From an … Continue Reading
Premium
Affimed Scraps Mono AFM13 To Focus on Combinations
Insights - Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both monotherapy and combination w/ NK. The monotherapy data … Continue Reading
Premium
Astria Runs Ahead of Phase 1 Readout
Insights - Astria (ATXS) expects preliminary results from Phase 1a trial of STAR-0215 by year end 2022. The trial aims to establish the prolonged half-life and demonstrate inhibition … Continue Reading
Premium
Jounce Announces Yet Another Delay
Insights - Jounce Announces Yet Another DelayJounce will be reporting their Phase 2 proof of concept data for their LILRB2/ILT4 target in the 1H 2023. This timeline … Continue Reading
PremiumAffimed Reports Early & Promising Activity for AFM24 Combination
Research - Affimed jumped yesterday after reporting unexpected activity of AFM24+atezolizumab in EGFR+ solid tumors. The initial results from the Phase 1 dose escalation study showed that … Continue Reading
Premium